RVT-501
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 528909

CAS#: 947620-48-6

Description: RVT-501, also known as E-6005, is a phosphodiesterase 4 (PDE-4) inhibitor potentially for the treatment of atopic dermatitis.


Price and Availability

Size
Price

10mg
USD 150
100mg
USD 750
1g
USD 3450
Size
Price

25mg
USD 250
200mg
USD 1150
2g
USD 4850
Size
Price

50mg
USD 450
500mg
USD 1950
5g
USD 7950

RVT-501 (E-6005), purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 528909
Name: RVT-501
CAS#: 947620-48-6
Chemical Formula: C26H24N4O5
Exact Mass: 472.1747
Molecular Weight: 472.5
Elemental Analysis: C, 66.09; H, 5.12; N, 11.86; O, 16.93


Synonym: E-6005; E6005; E6005; RVT-501; RVT501; RVT 501.

IUPAC/Chemical Name: methyl 4-((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)carbamoyl)benzoate

InChi Key: BBTFKAOFCSOZMB-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H24N4O5/c1-27-26-29-20-14-22(34-3)21(33-2)13-19(20)23(30-26)17-6-5-7-18(12-17)28-24(31)15-8-10-16(11-9-15)25(32)35-4/h5-14H,1-4H3,(H,28,31)(H,27,29,30)

SMILES Code: O=C(OC)C1=CC=C(C(NC2=CC=CC(C3=C4C=C(OC)C(OC)=CC4=NC(NC)=N3)=C2)=O)C=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:

Safety Data Sheet (MSDS):

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Nemoto O, Hayashi N, Kitahara Y, Furue M, Hojo S, Nomoto M, Shima S; Japanese E6005 Study Investigators.. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial. J Dermatol. 2016 Aug;43(8):881-7. doi: 10.1111/1346-8138.13231. PubMed PMID: 26703371.

2: Mano Y, Ishii T, Hotta K, Kusano K. Validation of a UPLC-MS/MS method for the simultaneous determination of E6005, a phosphodiesterase 4 inhibitor, and its metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Aug 15;998-999:31-9. doi: 10.1016/j.jchromb.2015.06.023. PubMed PMID: 26149248.

3: Furue M, Kitahara Y, Akama H, Hojo S, Hayashi N, Nakagawa H; JAPANESE E6005 Study Investigators.. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014 Jul;41(7):577-85. doi: 10.1111/1346-8138.12534. PubMed PMID: 24942594.

4: Ohba F, Nomoto M, Hojo S, Akama H. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. J Dermatolog Treat. 2016;27(3):241-6. doi: 10.3109/09546634.2015.1093587. PubMed PMID: 26581111.

5: Ohba F, Matsuki S, Imayama S, Matsuguma K, Hojo S, Nomoto M, Akama H. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: An investigator-blinded, vehicle-controlled study. J Dermatolog Treat. 2016 Oct;27(5):467-72. doi: 10.3109/09546634.2016.1157257. PubMed PMID: 27080209.

6: Andoh T, Kuraishi Y. Antipruritic mechanisms of topical E6005, a phosphodiesterase 4 inhibitor: inhibition of responses to proteinase-activated receptor 2 stimulation mediated by increase in intracellular cyclic AMP. J Dermatol Sci. 2014 Dec;76(3):206-13. doi: 10.1016/j.jdermsci.2014.10.005. PubMed PMID: 25458869.

7: Wakita H, Ohkuro M, Ishii N, Hishinuma I, Shirato M. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves. Exp Dermatol. 2015 Mar;24(3):215-6. doi: 10.1111/exd.12606. PubMed PMID: 25431172.

8: Kubota S, Watanabe M, Shirato M, Okuno T, Higashimoto I, Machida K, Yokomizo T, Inoue H. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice. Eur J Pharmacol. 2015 Dec 5;768:41-8. doi: 10.1016/j.ejphar.2015.10.013. PubMed PMID: 26455478.

9: Ishii N, Shirato M, Wakita H, Miyazaki K, Takase Y, Asano O, Kusano K, Yamamoto E, Inoue C, Hishinuma I. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12. doi: 10.1124/jpet.113.205542. PubMed PMID: 23674603.

10: Andoh T, Yoshida T, Kuraishi Y. Topical E6005, a novel phosphodiesterase 4 inhibitor, attenuates spontaneous itch-related responses in mice with chronic atopy-like dermatitis. Exp Dermatol. 2014 May;23(5):359-61. doi: 10.1111/exd.12377. PubMed PMID: 24645735.

11: Ishii N, Wakita H, Shirato M. Effect of the phosphodiesterase 4 inhibitor E6005 on nerve growth factor elevation in irritated skin of NC/Nga mice. J Dermatol Sci. 2014 Dec;76(3):263-4. doi: 10.1016/j.jdermsci.2014.09.010. PubMed PMID: 25455141.

12: Leaños-Miranda A, Méndez-Aguilar F, Ramírez-Valenzuela KL, Serrano-Rodríguez M, Berumen-Lechuga G, Molina-Pérez CJ, Isordia-Salas I, Campos-Galicia I. Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes. Medicine (Baltimore). 2017 Jan;96(4):e6005. doi: 10.1097/MD.0000000000006005. PubMed PMID: 28121958; PubMed Central PMCID: PMC5287982.

13: Mano Y, Kita K, Kusano K. Hematocrit-independent recovery is a key for bioanalysis using volumetric absorptive microsampling devices, Mitra™. Bioanalysis. 2015;7(15):1821-9. doi: 10.4155/bio.15.111. PubMed PMID: 26295984.

14: Nakamuta JS, Danoviz ME, Marques FL, dos Santos L, Becker C, Gonçalves GA, Vassallo PF, Schettert IT, Tucci PJ, Krieger JE. Cell therapy attenuates cardiac dysfunction post myocardial infarction: effect of timing, routes of injection and a fibrin scaffold. PLoS One. 2009 Jun 23;4(6):e6005. doi: 10.1371/journal.pone.0006005. PubMed PMID: 19547700; PubMed Central PMCID: PMC2695782.

15: Kuo I I, Fischer B, Vlahov D. Consideration of a North American heroin-assisted clinical trial for the treatment of opiate-dependent individuals. Int J Drug Policy. 2000 Sep 1;11(5):357-370. PubMed PMID: 10967518.